Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.34 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.34 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.33 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2170147 | 0.82 | VHL (0.39) | VHLMAPTADRB2ADRB1ADRB3 | |
| SCHEMBL4349489 | 0.81 | PPARA (0.44) | MAPTPPARASMN1; SMN2THRBLMNA | |
| SCHEMBL18530345 | 0.78 | HSP90AB1 (0.41) | VHLMAPTADRB2ADRB1ADRB3 | |
| SCHEMBL7423467 | 0.78 | VHL (0.38) | VHLMAPTNOTUMPPARASMN1; SMN2 | |
| SCHEMBL1706000 | 0.76 | SMN1; SMN2 (0.40) | VHLMAPTPPARASMN1; SMN2HPGD | |
| SCHEMBL10717593 | 0.76 | VHL (0.37) | VHLMAPTNOTUMPPARASMN1; SMN2 | |
| SCHEMBL6251 | 0.76 | VHL (0.60) | VHLMAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL11008691 | 0.76 | GABRA5 (0.42) | VHLMAPTNOTUMPPARASMN1; SMN2 | |
| SCHEMBL11374447 | 0.76 | PTGS1 (0.42) | VHLMAPTCHRNA4SMN1; SMN2LMNA | |
| SCHEMBL25218594 | 0.75 | NOTUM (0.50) | MAPTNOTUMSMN1; SMN2PTPN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092071-A1 | COMPOUNDS AND COMPOSITIONS AS SMARCA2/4 DEGRADERS AND USES THEREOF | UNIV MICHIGAN (US) | 2026-04-02 | — | — | US | disclosed |
| US-20250304596-A1 | PYRAZINE DERIVATIVES AND USES THEREOF | FOGHORN THERAPEUTICS INC (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250302832-A1 | PYRAZINE DERIVATIVES AND USES THEREOF | FOGHORN THERAPEUTICS INC (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250228944-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | ARVINAS OPERATIONS, INC. | 2025-07-17 | — | — | US | disclosed |
| CN-120035593-A | Pyrazine derivatives and uses thereof | 福宏治疗公司 | 2025-05-23 | — | — | CN | disclosed |
| WO-2025106637-A1 | CINNOLINE DERIVATIVES USEFUL AS BAF MODULATORS | FOGHORN THERAPEUTICS INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| CN-119998278-A | Compounds and uses thereof | 福宏治疗公司 | 2025-05-13 | — | — | CN | disclosed |
| EP-4522278-A1 | BENZOYPARAZINE PYRAZINES ANE THEIR USES | Foghorn Therapeutics Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-4522279-A1 | PYRAZINE DERIVATIVES AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-4522277-A1 | PYRAZINE DERIVATIVES AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-3337476-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | Arvinas, Inc. (US) | 2018-06-27 | — | — | EP | disclosed |
| US-20170065719-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | ARVINAS OPERATIONS, INC. | 2017-03-09 | — | — | US | disclosed |
| US-20170065719-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | ARVINAS OPERATIONS, INC. | 2017-03-09 | — | — | US | disclosed |
| US-20170065719-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | ARVINAS OPERATIONS, INC. | 2017-03-09 | — | — | US | disclosed |
| WO-2017030814-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | Arvinas, Inc. (US) | 2017-02-23 | — | — | WO | disclosed |
| WO-2017030814-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | Arvinas, Inc. (US) | 2017-02-23 | — | — | WO | disclosed |
| EP-0207955-B1 | PROCESS FOR THE PREPARATION OF 3,5-DISUBSTITUTED ISOXAZOLES | ZAMBON S.p.A. (IT) | 1990-02-07 | — | — | EP | disclosed |
| US-4772719-A | FROM DIHALOFORMALDOXIME AND ALKYNE, CYCLIZATION | ZAMBON S.P.A. (IT) | 1988-09-20 | — | — | US | disclosed |
| EP-0207955-A1 | PROCESS FOR THE PREPARATION OF 3,5-DISUBSTITUTED ISOXAZOLES. | ZAMBON SPA (IT) | 1987-01-14 | — | — | EP | disclosed |
| WO-1986003490-A1 | PROCESS FOR THE PREPARATION OF 3,5-DISUBSTITUTED ISOXAZOLES | ZAMBON S.P.A. (IT) | 1986-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302832-A1 | PYRAZINE DERIVATIVES AND USES THEREOF | BRCA1, VHL, SF3B5 | VHL 2/4885MAPT 3865/4885ADRB2 2477/4885 |
| US-20250304596-A1 | PYRAZINE DERIVATIVES AND USES THEREOF | VHL, BRCA1, SF3B5 | VHL 1/4885MAPT 3684/4885ADRB2 2405/4885 |
| US-20250228944-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | BRPF3, STUB1, BRDT | VHL 11/4885MAPT 2849/4885ADRB2 3884/4885 |
| US-20260092071-A1 | COMPOUNDS AND COMPOSITIONS AS SMARCA2/4 DEGRADERS AND USES THEREOF | SMARCC2, SMARCC1, SMARCA2 | VHL 763/4885MAPT 4582/4885ADRB2 260/4885 |
| US-20170065719-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | BRPF3, STUB1, BRDT | VHL 11/4885MAPT 2849/4885ADRB2 3884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.